AAPS PharmSciTech

, 10:858 | Cite as

Studies on the Effect of Water-Soluble Polymers on Drug–Cyclodextrin Complex Solubility

  • Rajashree S. Hirlekar
  • Suneeta N. Sonawane
  • Vilasrao J. Kadam
Research Article


The effect of complexation of irbesartan (IRB), a practically water-insoluble drug, with cyclodextrins in presence of different concentrations of water-soluble polymers (PEG 4000 and PVP K-90) on the dissolution rate of the drug has been investigated. Phase solubility studies were carried out to evaluate the solubilizing power of βCD in association with water-soluble polymers towards IRB and to determine the apparent stability constant (K S) of the complexes. Improvement in K S value for ternary complexes (IRB–βCD–polymers) clearly proved the benefit on the addition of water-soluble polymer to increase complexation efficiency. The dissolution rate of the drug from ternary systems containing PEG 4000 and PVP K-90 was higher as compared to the binary system. An optimum increase in the dissolution rate of the drug was observed at a polymer concentration of 5% w/w for PVP K-90 and 10% w/w for PEG 4000. DSC, FTIR, SEM, and XRD studies were carried out to characterize the complexes.

Key words

dissolution hydrophilic polymers irbesartan solubility β-cyclodextrin 







differential scanning calorimetry


Fourier transform infrared spectroscopy


X-ray diffraction


scanning electron microscopy


apparent stability constant




hydrochloric acid


  1. 1.
    Carrier RL, Miller LA, Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release. 2007;123:78–99.PubMedCrossRefGoogle Scholar
  2. 2.
    Loftsson T, Duchene D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329:1–11.PubMedCrossRefGoogle Scholar
  3. 3.
    Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilisers. Adv Drug Deliv Rev. 2007;59:645–66.PubMedCrossRefGoogle Scholar
  4. 4.
    S.C. Sweetman. Martindale-The Complete Drug Reference, ed: 34, pg no 940. London, 2005.Google Scholar
  5. 5.
    Pouleur HG. Clinical overview of irbesartan a new angiotensin II receptor antagonist. Am J Hypertens. 1997;10:318–24.CrossRefGoogle Scholar
  6. 6.
    Chawla G, Bansal AK. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci. 2007;32:45–57.PubMedCrossRefGoogle Scholar
  7. 7.
    Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins.1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Valero M, Perez-Revuelta BI, Rodriguez LJ. Effect of PVP K-25 on the formation of the naproxen:β-cyclodextrin complex. Int J Pharm. 2003;253:97–110.PubMedCrossRefGoogle Scholar
  9. 9.
    Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 2005;06:E329–57.CrossRefGoogle Scholar
  10. 10.
    Higuchi T, Connors KA. Phase solubility diagram. Adv Anal Chem Instr. 1965;4:117–212.Google Scholar
  11. 11.
    Ribeiro LSS, Ferreira DC, Veiga FJB. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with β-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci. 2003;20:253–66.PubMedCrossRefGoogle Scholar
  12. 12.
    Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Formulation and biological evaluation of glimepiride–cyclodextrin–polymer systems. Int J Pharm. 2006;309:129–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Liu L, Zhu S. Preparation and characterization of inclusion complexes of Prazosin hydrochloride with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. J Pharm Biomed Anal. 2006;40:122–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Patel AR, Vavia PR. Effect of hydrophilic polymer on solubilisation of fenofibrate by cyclodextrin complexation. J Incl Phenom Macroc Chem. 2006;56:247–51.CrossRefGoogle Scholar
  15. 15.
    Diaz MTE, Mfndez MG, Pfrez-Marcos MB, Vila-Jato JL, Torres-Labandeira JJ. Characterization and in vitro dissolution behaviour of ketoconazole/β-and 2-hydroxypropyl-β-cyclodextrin inclusion compounds. Int J Pharm. 1996;143:203–10.CrossRefGoogle Scholar
  16. 16.
    Figueiras A, Ribeiro L, Veira MT. Preparation and characterization of omeprazole:methyl–beta-cyclodextrininclusion complex in solid state. J Incl Phenom Macroc Chem. 2007;57:173–7.CrossRefGoogle Scholar
  17. 17.
    Naidu NB, Chowdary KPR, Murthy KVR, Satyanarayana V, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of meloxicam–cyclodextrin binary systems. J Pharm Biomed Anal. 2004;35:75–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Ammar HO, Salama HA, Mahmoud AA. Implication of inclusion complexation of glimepiride in cyclodextrin–polymer systems on its dissolution, stability and therapeutic efficacy. Int J Pharm. 2006;320:53–7.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2009

Authors and Affiliations

  • Rajashree S. Hirlekar
    • 1
  • Suneeta N. Sonawane
    • 1
  • Vilasrao J. Kadam
    • 1
  1. 1.Department of PharmaceuticsBharati Vidyapeeth’s College of PharmacyNavi MumbaiIndia

Personalised recommendations